DEINOVE to present data on DNV3837 at the ESCMID/ASM

• New key preclinical results and a case study excerpted from our ongoing phase II clinical trial
• DNV3681 in vitro efficacy is superior to vancomycin and similar to the gold standard, fidaxomicin
• The prodrug DNV3837 is rapidly converted to DNV3681 in vivo and the active drug mostly concentrates in the GI tract
• The use of DNV3837 is a potential paradigm shift for CDI treatment

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that a poster titled « DNV3837, a parenteral GI tract-targeted treatment for Clostridioides difficile infection » is to be presented at the ESCMID/ASM conference taking place in Dublin, from October 4 to 7.

The new preclinical data presented show that DNV3681 is highly efficient against 333 clinical isolates of Clostridioides difficile, and its efficacy is superior to vancomycin and similar to the gold standard, fidaxomicin.

Preclinical and clinical data show that the prodrug DNV3837 is rapidly converted to DNV3681 in vivo and that the active drug mostly concentrates in the GI tract. This unusual pharmacokinetic profile could be explained by a strong efflux of the active drug by the intestinal efflux pumps from the blood to the GI lumen.

The patient case presented suffers from a severe Clostridioides difficile infection. His White Blood Cells count, an inflammatory marker, rapidly dropped after inclusion, remained in the upper limit during 8 days and was normal at the end of the treatment. The diarrhea episodes improved after 6 days of treatment and came back to normal 10 days after treatment after a transient constipation period. DNV3681 concentrations in feces were several order of magnitude higher than DNV3681 MIC90¹.

Georges Gaudriault, Chief Scientific Officer of DEINOVE who attended the ESCMID/ASM conference in Dublin specifies: « The use of DNV3837 is a…